Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice

Maioli, Tatiani Uceli; Silva, Brenda de Melo; Dias, Michelle Nobre; Paiva, Nivea Carolina; Cardoso, Valbert Nascimento; Fernandes, Simone Odília Antunes; Carneiro, Cláudia Martins; Martins, Fernanda Pereira; Generoso, Simone de Vasconcelos

doi:10.1186/1477-5751-13-6

Cited by 40 publications

(24 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, not all the research studies demonstrated beneficial effects of probiotics on chemotherapy‐induced mucositis. Maioli et al . showed that Saccharomyces boulardii was not able to ameliorate the effects of mucositis induced by 5‐FU.…”

Section: Discussionmentioning

confidence: 99%

Modulations of probiotics on gut microbiota in a 5‐fluorouracil‐induced mouse model of mucositis

Yeung

Chiau

Cheng

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim:Intestinal mucositis remained one of the most deleterious complications in cancer patients undergoing chemotherapy. 5-FU treatment was reported to affect the abundance of gut microbiota and cause mucositis, which might be ameliorated by probiotics. We investigate the potential changes of 5-FU treatment and the modulations of probiotics on gut microbiota in a mouse model. Methods: Male BALB/c mice received either 5-FU or saline (S). They were separated and fed saline, Lactobacillus casei variety rhamnosus (Lcr) and Lactobacillus reuteri DSM 17938 (BG). Lcr and BG were simultaneously administered with 5-FU for 5 days. Stool specimens were collected for DNA extraction and pyrosequenced for bioinformatic analysis. Results: Fecal microbial communities were obviously diverse. Bacteroides and Bacteroidaceae were the most abundant microbiota in FU.BG group while S24_7 was the most in S.S group. At phylum and class levels, abundances of Betaproteobacteria, Erysipelotrichi, Gammaproteobacteria, and Verrucomicrobia were significantly increased in the FU groups. Probiotics supplementation did increase the abundances of Enterobacteriales and Turicibacterales. We demonstrated that probiotics did modulate the abundance and diversity of gut microbiota. Bacterial motility proteins were found enriched and upregulated in the S.BG group. No mortality was noted. No bacterial translocation was found in spleen and blood among the six groups. Conclusion: Gut microbiota of mice undergoing chemotherapy exhibited a distinct disruption in bacterial composition. Probiotic did modulate the abundance and diversity of gut microbiota. This is the first study to analyze the effects and safety of Lactobacillus strains on 5-FU-induced mucositis systematically and assess changes in the intestinal microbiota after probiotic intervention.Additional supporting information may be found online in the Supporting Information section at the end of the article. Data S1. Supporting information.

show abstract

Section: Discussionmentioning

confidence: 99%

Modulations of probiotics on gut microbiota in a 5‐fluorouracil‐induced mouse model of mucositis

Yeung

Chiau

Cheng

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…The intestinal permeability was evaluated according to Maioli et al (2014). All mice received 0.1 ml diethylenetriaminepentaacetic acid (Nuclefar) solution labelled with 18.5 MBq of 99m-technetium by gavage.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice

et al. 2015

View full text Add to dashboard Cite

Mucositis is one of the most debilitating side effects of chemotherapy and some previous studies suggest a role for indigenous microbiota in the course of this pathology. Therefore, the aim of our study was to evaluate the differences in phenotype between germ-free (GF) and conventional (CV) mice, and the role of b-glucuronidase-producing bacteria in the development of irinotecan treatment in a murine model. After mucositis induction, CV mice showed a significant increase in all inflammatory parameters when compared to GF mice. CV animals also showed more lesions of the intestinal epithelium, coherent with their higher intestinal permeability. The conventionalization of GF animals reversed their phenotype to that found in CV mice. In addition, gnotobiotic mice monoassociated with an Escherichia coli strain producing b-glucuronidase showed an increased permeability when compared to gnotobiotic mice monoassociated with an E. coli strain deleted for the gene encoding b-glucuronidase, but these did not show any differences in the influx of neutrophils, eosinophils or histological characteristics. Our data confirmed that components of the gut microbiota are involved in the signs of mucositis. Nevertheless, other mechanisms than this enzyme are involved in the irinotecan treatment, since the monoassociation was not able to restore the entire phenotype observed in the CV animals with irinotecan treatment in our murine model.

show abstract

“…Chemotherapy-induced mucositis can limit the dose of chemotherapy and increase the risk of infection or hospitalization. Consequently, mucositis during chemotherapy could increase clinical and economic burdens (4). 5-Fluorouracil (5-FU) is a frequently prescribed anticancer agent; however, it commonly causes chemotherapy-related mucositis.…”

Section: Introductionmentioning

confidence: 99%

Ursodeoxycholic acid attenuates 5‑fluorouracil‑induced mucositis in a rat model

et al. 2018

View full text Add to dashboard Cite

Intestinal mucositis is a commonly encountered complication of chemotherapy. However, there are few effective treatments or preventive methods. Ursodeoxycholic acid (UDCA) stabilizes cell membranes, acts as an antioxidant and inhibits apoptosis, thereby exerting cytoprotective effects. The aim of the present study was to examine the ability of UDCA to protecting against chemotherapy-associated mucositis. Sprague-Dawley rats were randomly assigned to five groups: Control, vehicle + 5-fluorouracil (5-FU), 5-FU + UDCA (10 mg/kg/day), 5-FU + UDCA (100 mg/kg/day) and 5-FU + UDCA (500 mg/kg/day). Following randomization, a single dose of 5-FU was injected and varying amounts of UDCA was administered to each group. UDCA was administered orally to rats for 6 days, beginning 1 day prior to 5-FU administration. The rats were sacrificed 1 day following the last UDCA administration and intestinal tissue specimens were prepared for analysis. UDCA administration attenuated body weight loss, decreased inflammatory cytokine levels and curbed intestinal villus damage in the 10 and 100 mg/kg/day groups. When compared with the jejunal villi lengths in the vehicle+5-FU group (212.8±58.0 µm), those in the 5-FU + UDCA (10 mg/kg/day) and 5-FU + UDCA (100 mg/kg/day) groups were significantly greater [331.3±18.0 µm (P=0.001) and 310.0±112.6 µm (P=0.046), respectively]. Tumor necrosis factor-α and interleukin-6 levels were reduced in the 10 and 100 mg/kg/day UDCA groups (P<0.05). UDCA considerably attenuated the elevation in inflammatory cytokines and intestinal villus damage. The results of the study suggest that UDCA may be used as a protective agent against chemotherapy-associated intestinal mucositis.

show abstract

Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice

Cited by 40 publications

References 43 publications

Modulations of probiotics on gut microbiota in a 5‐fluorouracil‐induced mouse model of mucositis

Modulations of probiotics on gut microbiota in a 5‐fluorouracil‐induced mouse model of mucositis

Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice

Ursodeoxycholic acid attenuates 5‑fluorouracil‑induced mucositis in a rat model

Contact Info

Product

Resources

About